Stock listing
Frankfurt:2TK Eledon Pharmaceuticals, Inc. Aktie
German listing (Frankfurt) of Eledon Pharmaceuticals, Inc. · home listing NASDAQ:ELDN
Follow Eledon Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · FWB:2TK
€1.83 EUR +0.07 (+4.0%)
Close on Nov 19, 2026
- Day range
- €1.83 – €1.83 EURNov 19, 2026
- Market cap
- €148.7M EURAt the close on Nov 19, 2026 · price × 81.26M shares outstanding
- 52-week range
- €1.16 – €3.62 EURLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- €883 EURMedian day 0 shares · 45 days with no trades · last 3 months, Aug 19, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ELDN · Home | $1.78 USD | -0.25 (-12.3%) | 1,292,761 | $1.87 | $2.00 | $1.76 | $2.03 | Close on Nov 20, 2026 |
| Frankfurt:2TK | €1.83 EUR | +0.07 (+4.0%) | — | €1.83 | €1.83 | €1.83 | €1.76 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 6, 2026 · FWB:2TK · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.139 | -0.168 | -7.3% | €2.139 | €2.139 | €2.139 | 0 | |
| €2.307 | +0.047 | +2.1% | €2.307 | €2.307 | €2.307 | 168 | |
| €2.26 | +0.004 | +0.2% | €2.26 | €2.26 | €2.26 | 168 | |
| €2.256 | -0.166 | -6.9% | €2.256 | €2.256 | €2.256 | 0 | |
| €2.422 | -0.171 | -6.6% | €2.422 | €2.422 | €2.422 | 0 | |
| €2.593 | +0.21 | +8.8% | €2.593 | €2.593 | €2.593 | 1,000 | |
| €2.383 | +0.292 | +14.0% | €2.383 | €2.383 | €2.383 | 11,780 | |
| €2.091 | +0.164 | +8.5% | €2.091 | €2.091 | €2.091 | 892 | |
| €1.927 | -0.072 | -3.6% | €1.927 | €1.927 | €1.927 | 0 | |
| €1.999 | +0.001 | +0.1% | €1.999 | €1.999 | €1.999 | 0 | |
| €1.998 | +0.069 | +3.6% | €1.998 | €1.998 | €1.998 | 0 | |
| €1.929 | -0.04 | -2.0% | €1.929 | €1.929 | €1.929 | 0 | |
| €1.969 | +0.102 | +5.5% | €1.969 | €1.969 | €1.969 | 0 | |
| €1.867 | +0.015 | +0.8% | €1.867 | €1.867 | €1.867 | 0 | |
| €1.852 | -0.062 | -3.2% | €1.852 | €1.852 | €1.852 | 0 | |
| €1.914 | -0.016 | -0.8% | €1.961 | €1.961 | €1.91 | 0 | |
| €1.93 | -0.092 | -4.5% | €1.93 | €1.93 | €1.93 | 0 | |
| €2.022 | -0.093 | -4.4% | €2.022 | €2.022 | €2.022 | 0 | |
| €2.115 | -0.042 | -1.9% | €2.115 | €2.115 | €2.115 | 0 | |
| €2.157 | +0.055 | +2.6% | €2.157 | €2.157 | €2.157 | 0 | |
| €2.102 | -0.012 | -0.6% | €2.102 | €2.102 | €2.102 | 2,000 | |
| €2.114 | -0.01 | -0.5% | €2.114 | €2.114 | €2.114 | 800 | |
| €2.124 | -0.065 | -3.0% | €2.124 | €2.124 | €2.124 | 0 | |
| €2.189 | +0.03 | +1.4% | €2.189 | €2.189 | €2.189 | 0 | |
| €2.159 | +0.051 | +2.4% | €2.159 | €2.159 | €2.159 | 0 | |
| €2.108 | -0.069 | -3.2% | €2.108 | €2.108 | €2.108 | 0 | |
| €2.177 | +0.037 | +1.7% | €2.177 | €2.177 | €2.177 | 0 | |
| €2.14 | -0.115 | -5.1% | €2.14 | €2.14 | €2.14 | 0 | |
| €2.255 | -0.024 | -1.1% | €2.255 | €2.255 | €2.255 | 0 | |
| €2.279 | -0.09 | -3.8% | €2.279 | €2.279 | €2.279 | 0 | |
| €2.369 | +0.039 | +1.7% | €2.313 | €2.392 | €2.311 | 3,086 | |
| €2.33 | -0.125 | -5.1% | €2.328 | €2.362 | €2.322 | 800 | |
| €2.455 | +0.171 | +7.5% | €2.455 | €2.455 | €2.455 | 0 | |
| €2.284 | -0.07 | -3.0% | €2.284 | €2.284 | €2.284 | 0 | |
| €2.354 | +0.122 | +5.5% | €2.367 | €2.373 | €2.353 | 500 | |
| €2.232 | -0.046 | -2.0% | €2.232 | €2.232 | €2.232 | 166 | |
| €2.278 | 0.00 | 0.0% | €2.278 | €2.278 | €2.278 | 0 | |
| €2.278 | -0.051 | -2.2% | €2.278 | €2.278 | €2.278 | 0 | |
| €2.329 | +0.011 | +0.5% | €2.329 | €2.329 | €2.329 | 0 | |
| €2.318 | -0.025 | -1.1% | €2.318 | €2.318 | €2.318 | 0 | |
| €2.343 | -0.025 | -1.1% | €2.343 | €2.343 | €2.343 | 500 | |
| €2.368 | -0.208 | -8.1% | €2.368 | €2.368 | €2.368 | 0 | |
| €2.576 | +0.067 | +2.7% | €2.463 | €2.591 | €2.441 | 50 | |
| €2.509 | 0.00 | 0.0% | €2.509 | €2.509 | €2.509 | 0 | |
| €2.509 | +0.049 | +2.0% | €2.509 | €2.509 | €2.509 | 0 | |
| €2.46 | -0.052 | -2.1% | €2.46 | €2.46 | €2.46 | 0 | |
| €2.512 | -0.014 | -0.6% | €2.512 | €2.512 | €2.512 | 0 | |
| €2.526 | +0.041 | +1.6% | €2.526 | €2.526 | €2.526 | 0 | |
| €2.485 | -0.198 | -7.4% | €2.485 | €2.485 | €2.485 | 0 | |
| €2.683 | -0.094 | -3.4% | €2.683 | €2.683 | €2.683 | 0 | |
| €2.777 | -0.024 | -0.9% | €2.777 | €2.777 | €2.777 | 0 | |
| €2.801 | -0.067 | -2.3% | €2.801 | €2.801 | €2.801 | 0 | |
| €2.868 | +0.034 | +1.2% | €2.868 | €2.868 | €2.868 | 0 | |
| €2.834 | -0.018 | -0.6% | €2.834 | €2.834 | €2.834 | 0 | |
| €2.852 | -0.053 | -1.8% | €2.852 | €2.852 | €2.852 | 0 | |
| €2.905 | -0.044 | -1.5% | €2.905 | €2.905 | €2.905 | 0 | |
| €2.949 | -0.069 | -2.3% | €2.949 | €2.949 | €2.949 | 0 | |
| €3.018 | +0.037 | +1.2% | €3.018 | €3.018 | €3.018 | 0 |
Splits
2 splits since 2017 · FWB:2TK · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-18 | Consolidation | |
| 1-for-9 | Consolidation |
- Ticker
- Frankfurt:2TK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 33 slides
Latest news
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Oct 26, 2026
Closed €2.00 (+0.1%) on Oct 26, 2026
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Oct 5, 2026
Closed €2.19 (+1.4%) on Oct 6, 2026
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Sep 22, 2026
Closed €2.28 (-3.0%) on Sep 22, 2026
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
Sep 9, 2026
Closed €2.58 (+2.7%) on Sep 9, 2026
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Sep 3, 2026
Closed €2.51 (-0.6%) on Sep 3, 2026
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 13, 2026
Closed €3.10 (-3.0%) on Aug 14, 2026
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Jun 22, 2026
Closed €3.32 (0.0%) on Jun 22, 2026
Eledon Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 97 in all · newest Nov 12, 2026 · oldest 2021
- Calls
- 10 calls with a replay · 10 with a transcript · latest May 9, 2024
- Decks
- 7 decks · latest September 2026
Where Eledon Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ELDN · Home listing | NASDAQ | United States | USD |
| BOATS:ELDN | BOATS | United States | USD |
| Lang & Schwarz:A2QL00 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2QL00 | LS Exchange | Germany | EUR |
| Tradegate:2TK | Tradegate | Germany | EUR |
| Dusseldorf:2TK | Dusseldorf | Germany | EUR |
| Frankfurt:2TK · This page | Frankfurt | Germany | EUR |
| Munich:2TK | Munich | Germany | EUR |
| Stuttgart:2TK | Stuttgart | Germany | EUR |
Valuation
Price/book 4.9× against a median of 1.6×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $80.67M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 4.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.95
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| BioVersys AG · SIX:BIOV | US$154.1M | US$97.45M | n/a | 102× | n/a | 2.9× | n/a | 0.5× | n/a |
| InflaRx N.V. · NASDAQ:IFRX | US$153.3M | US$135.7M | n/a | 4,215× | n/a | 19.5× | n/a | 0.0× | 1.61 |
| Polaris Group · TWSE:6550 | US$153.0M | US$154.8M | n/a | 75.1× | n/a | 1.1× | n/a | 0.5× | n/a |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541 | US$152.0M | US$64.59M | n/a | 2.9× | n/a | 1.6× | −141.7% | 0.6× | n/a |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.73M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| Median of the others | US$151.1M | US$81.02M | 8.4× | 73.9× | 5.2× | 1.6× | −155.7% | 0.1× | 1.50 |
Forecasts
6 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.93 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David-Alexandre C. Gros | CEO and Director |
| Paul Little | Chief Financial Officer |
| Steven Perrin | President and Chief Scientific Officer |
| Bryan Smith | General Counsel |
| Carlos Candido | Vice President, Cell Therapy Operations |
| John Herberger | Vice President, Technical Operations |
| Marcela Laurito-Trammell | Vice President, Clinical Development – Transplantation |
| Marina Escudero | Vice President, and Head of Clinical Operations |
| Sepideh Habibi | Vice President, and Head of Safety & Pharmacovigilance |
| Yulan Li | Vice President, Biometrics |
| David Hovland | Chief Regulatory Officer |
Board
| Director | Role |
|---|---|
| Keith A. Katkin | Chairman of the Board of Directors |
| Allan Kirk | Director |
| David-Alexandre C. Gros | CEO and Director |
| James Robinson | Director |
| Jan Hillson | Director |
| John S. McBride | Director |
| June Lee | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2023 Earnings Call | Thu, May 11, 2023 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q4 2022 Earnings Call | Thu, Mar 30, 2023 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q2 2022 Earnings Call | Thu, Aug 11, 2022 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2022 Earnings Call | Thu, May 12, 2022 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q4 2021 Earnings Call | Thu, Mar 24, 2022 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q3 2021 Earnings Call | Thu, Nov 11, 2021 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 4:30 PM ET | Replay |
| Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2021 Earnings Call | Thu, May 13, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −10.6% |
| Q2 2026 | Aug 13, 2026 · After close | −4.3% |
| Q1 2026 | May 7, 2026 | +2.1% |
| Q4 2025 | Mar 19, 2026 · After close | +1.1% |
| Q3 2025 | Nov 14, 2025 · After close | −8.0% |
| Q2 2025 | Aug 14, 2025 · After close | +1.1% |
| Q1 2025 | May 14, 2025 · After close | +2.1% |
| Q4 2024 | Mar 26, 2025 · Before open | −2.9% |
| Q3 2024 | Nov 12, 2024 · After close | −11.4% |
| Q2 2024 | Aug 19, 2024 · After close | +3.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +6.8% |
| Q4 2023 | Mar 28, 2024 · After close | −3.4% |
| Q3 2023 | Nov 9, 2023 · After close | +0.9% |
| Q2 2023 | Aug 10, 2023 · Before open | +1.6% |
| Q1 2023 | May 11, 2023 · After close | −13.0% |
| Q4 2022 | Mar 30, 2023 · After close | −6.0% |
| Q3 2022 | Nov 14, 2022 · After close | −3.6% |
| Q2 2022 | Aug 11, 2022 · After close | −1.1% |
| Q1 2022 | May 12, 2022 · After close | +9.9% |
| Q4 2021 | Mar 24, 2022 · After close | +4.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 33 slides | September 2026 |
| Technical Presentation (November 2025) | Technical | 32 slides | Nov 7, 2025 |
| Investor Day (July 2025) | Investor day | 114 slides | Jul 9, 2025 |
| Technical Presentation (November 2023) | Technical | 15 slides | Nov 2, 2023 |
| Investor Presentation (January 2023) | Investor deck | 25 slides | Jan 9, 2023 |
| Technical Presentation (May 2022) | Technical | 21 slides | May 31, 2022 |
| Technical Presentation | Technical | 18 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$57.5M raised · US$1.65 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Cantor (co-lead), LifeSci Capital (co-lead) Use of proceeds: Advance tegoprubart programs in kidney transplantation, islet cell transplantation and xenotransplantation | Nov 14, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Tokai Pharmaceuticals Inc. Priced at US$15.00 a share on Sep 16, 2014.
- Price
- US$15.00 a share
- Shares offered
- 6,480,000 shares of common stock
- Offering size
- US$97.2 million
- Underwriters' option
- Up to 972,000 more shares
- Underwriters
- BMO Capital Markets, Stifel, William Blair, Janney Montgomery Scott · In the order on the cover
- Shares delivered
- On or about Sep 22, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 2, 2014 |
| Filed publicly | Aug 11, 2014 |
| Amended once | Sep 2, 2014 |
| Shares registered with an exchange | Sep 12, 2014 |
| Declared effective by the SEC | Sep 16, 2014 |
| Final prospectus, with the price | Sep 18, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 18, 2014 |
| FWP · Free writing prospectus | Sep 17, 2014 |
| EFFECT · Notice that a registration is effective | Sep 16, 2014 |
| S-1MEF · Registration of more shares for the same offering | Sep 16, 2014 |
| CORRESP · Letter to the SEC | Sep 12, 2014 |
| CORRESP · Letter to the SEC | Sep 12, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Sep 12, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 12, 2014 |
| S-1/A · Registration statement, amended | Sep 2, 2014 |
| CORRESP · Letter to the SEC | Aug 25, 2014 |
All 15 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Aug 11, 2014 |
| DRS/A · Draft registration statement, amended | Jul 16, 2014 |
| DRS/A · Draft registration statement, amended | Jun 27, 2014 |
| UPLOAD · Letter from the SEC | May 30, 2014 |
| DRS · Draft registration statement | May 2, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 120.0K | 120.0K | 0 | 0 | 0 | 0 |
| Cost of revenue | 359.0K | 374.0K | 373.0K | 195.0K | 183.0K | 182.0K | 11.0K | 22.0K | 35.0K | |
| Gross profit | -359.0K | -374.0K | -373.0K | 120.0K | -183.0K | -182.0K | -11.0K | -22.0K | -35.0K | |
| Research and development | 66.3M | 52.0M | 30.3M | 27.1M | 23.7M | 6.13M | 8.13M | 6.82M | 2.02M | 3.19M |
| Selling, general and administrative | 17.0M | 18.6M | 12.7M | 12.7M | 13.1M | 10.1M | 6.06M | 7.24M | 11.1M | 13.1M |
| Operating income | -83.3M | -70.6M | -43.0M | -88.4M | -36.9M | -18.5M | -16.1M | -14.1M | -13.1M | -5.13M |
| Depreciation and amortization | 313.0K | 359.0K | 374.0K | 373.0K | 195.0K | 5.00K | 9.00K | 11.0K | 22.0K | 35.0K |
| EBITDA | -82.9M | -70.2M | -42.6M | -88.1M | -36.7M | -18.5M | -16.0M | -14.0M | -13.1M | -5.09M |
| Interest expense | 462.0K | 202.0K | 9.66M | 0 | 0 | 0 | 0 | |||
| Income before tax | -45.6M | -35.8M | -116.5M | -88.0M | -36.9M | -23.2M | -16.0M | -14.1M | -13.1M | -5.66M |
| Income tax | 35.0K | 431.0K | 0 | 0 | -2.35M | -404.0K | 1.87M | -5.00K | 0 | |
| Net income | -45.6M | -36.2M | -116.5M | -88.0M | -34.5M | -22.8M | -16.0M | -14.1M | -13.1M | -5.66M |
| Earnings per share, basic | -0.52 | -0.66 | -4.73 | -6.16 | -2.33 | -15.72 | -24.42 | -1.56 | -2.30 | -2.46 |
| Earnings per share, diluted | -0.52 | -0.66 | -4.73 | -6.16 | -2.33 | -15.72 | -24.42 | -1.56 | -2.30 | -2.46 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 22.8M | 20.5M | 4.61M | 56.4M | 84.8M | 114.2M | 8.79M | 13.0M | 17.2M | 1.10M |
| Short-term investments | 110.5M | 119.6M | 46.5M | 0 | 4.17M | |||||
| Receivables | 514.0K | 110.0K | 245.0K | 594.0K | ||||||
| Inventory | 1.29M | 881.0K | ||||||||
| Current assets | 135.7M | 143.7M | 56.1M | 59.5M | 88.3M | 115.6M | 9.97M | 14.3M | 19.0M | 1.15M |
| Property, plant and equipment | 768.0K | 138.0K | 5.00K | 14.0K | 25.0K | 31.0K | ||||
| Goodwill | 0 | 0 | 48.6M | 48.6M | 0 | 1.87M | 1.87M | |||
| Total assets | 169.0M | 177.4M | 89.1M | 92.8M | 170.5M | 197.2M | 10.9M | 17.0M | 20.9M | 1.20M |
| Accounts payable | 3.63M | 5.83M | 967.0K | 2.20M | 1.81M | 1.37M | 329.0K | 689.0K | 418.0K | 338.0K |
| Current liabilities | 18.3M | 11.6M | 3.90M | 6.47M | 4.40M | 2.48M | 1.32M | 2.53M | 1.44M | 3.90M |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.45M | ||
| Total liabilities | 32.2M | 59.3M | 81.9M | 8.61M | 6.55M | 6.59M | 1.47M | 2.53M | 1.44M | 3.90M |
| Shareholders' equity | 81.1M | 62.4M | -48.5M | 23.8M | 164.0M | 190.6M | 9.46M | 14.5M | 19.5M | -2.70M |
| Shares outstanding | 75.4M | 59.8M | 24.2M | 13.8M | 14.3M | 15.2M | 720.4K | 9.42M | 7.11M | 394.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -62.3M | -47.3M | -39.5M | -28.4M | -28.9M | -15.2M | -13.9M | -11.9M | -14.9M | -4.92M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9.00K |
| Free cash flow | -62.3M | -47.3M | -39.5M | -28.4M | -28.9M | -15.2M | -13.9M | -11.9M | -14.9M | -4.93M |
| Cash from investing | 10.8M | -70.3M | -45.3M | 11.0M | 11.0M | 11.0M | 23.3M | 1.00K | ||
| Cash from financing | 53.8M | 133.5M | 33.0M | 33.0M | -449.0K | 109.6M | 9.68M | 7.56M | 7.87M | 2.93M |
| Dividends paid | -25.0K | |||||||||
| Share buybacks | -25 | |||||||||
| Change in cash | 2.26M | 15.9M | -51.8M | -28.4M | -29.4M | 105.4M | -4.18M | -4.33M | 16.2M | -1.99M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Sep 4, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 7, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 7, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 1, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2026 | Financing | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 14, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Aug 14, 2025 | Annual report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 14, 2025 | Current report | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 20, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 5, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 31, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 31, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 31, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Oct 30, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Oct 30, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 29, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 3, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 1, 2024 | Financing | SEC |
| CORRESP · Letter to the SEC | Sep 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 26, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 20, 2024 | Material contract | SEC |
| S-3 · Registration statement | Sep 20, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 19, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 19, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Aug 19, 2024 | Annual report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2024 | Explanation request | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| 8-K · Current report | Jul 10, 2024 | Financing | SEC |
| 8-K · Current report | Jul 10, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 6, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 30, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | May 30, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 30, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 30, 2024 | Meeting notice | SEC |
| S-3 · Registration statement | May 24, 2024 | Offer document | SEC |
| D | May 22, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 8-K · Current report | May 7, 2024 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 26, 2024 | Annual report | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Nov 2, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 20, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 13, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Aug 10, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 8-K · Current report | Jun 21, 2023 | Management or board change | SEC |
| 424B3 · Prospectus | Jun 8, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 5, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 31, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 24, 2023 | Other filings | SEC |
| D | May 22, 2023 | Other filings | SEC |
| S-3 · Registration statement | May 18, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 4 · Change in ownership | May 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| DEF 14A · Proxy statement | May 1, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 1, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 1, 2023 | Meeting notice | SEC |
| 8-K · Current report | May 1, 2023 | Material contract | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2023 | Current report | SEC |
| 4 · Change in ownership | Nov 23, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 8-K · Current report | Jun 22, 2022 | Meeting outcome | SEC |
| 8-K · Current report | May 31, 2022 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2022 | Meeting notice | SEC |
| 10-K · Annual report | Mar 24, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2022 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2022 | Insider trade | SEC |
This page holds 200 of 617 filings. Open Filings
Cap table
Built by 6ix from Eledon Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 84,459,713
- Fully diluted
- 84,459,713
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 84,459,713 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 84,459,713 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gary A. Lyons Other companies: Travere Therapeutics, Inc. (Director · Since at least Oct 8, 2014); Neurocrine Biosciences, Inc. (Director · Since at least May 25, 2010); Brickell Biotech Inc (Director · Feb 14, 2020 – May 17, 2022 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); NeurogesX Inc (Director · Apr 27, 2011 – Jun 7, 2012 · Past); Rigel Pharmaceuticals, Inc. (Director · May 28, 2010 – May 26, 2023 · Past); Vical Incorporated (Director · May 25, 2010 – May 23, 2018 · Past); Facet Biotech Corp (Director · Apr 20, 2010 – Apr 21, 2010 · Past) | Director · May 10, 2017 – May 1, 2023 · Past |
| Timothy J Barberich Other companies: TScan Therapeutics, Inc. (Director · Jul 15, 2021 – Dec 18, 2023 · Past); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Rocket Pharmaceuticals, Inc. (Director · Sep 28, 2016 – Jun 20, 2017 · Past); Verastem, Inc. (Director · Mar 10, 2014 – Jun 28, 2021 · Past); HeartWare International Inc (Director · Apr 29, 2008 – Aug 23, 2016 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Director · Mar 16, 2006 – Oct 20, 2009 · Past) | Director · Sep 16, 2014 – Jun 15, 2016 · Past |
| Keith A. Katkin Other companies: Emergent BioSolutions Inc. (Independent Director · Since at least Apr 1, 2022); Syndax Pharmaceuticals, Inc. (Director · Since at least Mar 29, 2017); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Sep 26, 2018 – Feb 19, 2020 · Past); Rigel Pharmaceuticals, Inc. (Director · Jun 29, 2015 – May 19, 2021 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Avanir Pharmaceuticals Inc (President and CEO, Director · May 15, 2013 – Dec 15, 2014 · Past) | Chairman of the Board of Directors · Since at least May 10, 2017 |
| James A Robinson Jr Other companies: UroGen Pharma Ltd. (Director · Since at least Jul 25, 2023); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Mar 1, 2019 – Mar 29, 2021 · Past); Neos Therapeutics Inc (Director · Jan 29, 2019 – Mar 19, 2021 · Past); Alkermes plc (President & COO,Alkermes, Inc. · Mar 5, 2018 – Apr 4, 2019 · Past) | Director · Since at least Oct 1, 2023 |
| Christine Ocampo Other companies: Urovant Sciences Ltd (PAO; CAO/Urovant Sciences,Inc. · Sep 26, 2018 – Mar 29, 2021 · Past); Avanir Pharmaceuticals Inc (Vice President, Finance · Aug 11, 2010 – Dec 16, 2014 · Past) | See Remarks · May 10, 2017 – May 24, 2017 · Past |
| David-Alexandre C. Gros Other companies: Neurocrine Biosciences, Inc. (President & COO · Jan 9, 2017 – Feb 6, 2017 · Past); Alnylam Pharmaceuticals, Inc. (SVP, Chief Business Officer · Jun 8, 2015 – Dec 20, 2016 · Past) | CEO and Director · Since at least Sep 9, 2020 |
| Lee Kalowski Other companies: Q32 Bio Inc. (PRESIDENT & CHIEF FINANCIAL OFFICER · Since at least Mar 25, 2024); Bicycle Therapeutics PLC (President and CFO · May 22, 2019 – Apr 3, 2023 · Past) | Chief Financial Officer · Sep 16, 2014 – Dec 15, 2015 · Past |
| Bryan Smith Other companies: Urovant Sciences Ltd (GC/Urovant Sciences, Inc. · Sep 26, 2018 – Mar 29, 2021 · Past) | General Counsel · Since at least Apr 19, 2021 |
| Catherine C Turkel Other companies: Lexaria Bioscience Corp. (Director · Sep 2, 2022 – Aug 12, 2024 · Past) | President · May 20, 2019 – Mar 19, 2020 · Past |
| Gerald E Quirk Other companies: Syros Pharmaceuticals, Inc. (Chief Legal & Compliance Offic · Sep 26, 2016 – Nov 19, 2024 · Past) | General Counsel, Executive VP · May 26, 2015 – Dec 15, 2015 · Past |
All 27 people
| Person | Seat |
|---|---|
| Jon Kuwahara Other companies: Emmaus Life Sciences, Inc. (Director · Oct 1, 2024 – Oct 1, 2024 · Past) | See Remarks · May 20, 2019 – Sep 11, 2020 · Past |
| June Lee Other companies: Tenaya Therapeutics, Inc. (Board Member · Since at least Oct 18, 2024) | Director · Since at least Jan 10, 2025 |
| Stephen Buckley Jr Other companies: Enanta Pharmaceuticals, Inc. (Director · Mar 20, 2013 – Feb 28, 2019 · Past) | Director · Jan 8, 2015 – Jun 15, 2016 · Past |
| Allan Kirk | Director · Since at least Jul 17, 2025 |
| Carlos Candido | Vice President, Cell Therapy Operations · Since at least Nov 4, 2026 |
| David Hovland | Chief Regulatory Officer · Since at least Nov 4, 2026 |
| James Robinson | Director · Since at least Nov 5, 2026 |
| Jan Hillson | Director · Since at least Jan 10, 2026 |
| John Herberger | Vice President, Technical Operations · Since at least Nov 4, 2026 |
| John S. McBride | Director · Since at least Feb 1, 2022 |
| Marcela Laurito-Trammell | Vice President, Clinical Development – Transplantation · Since at least Nov 4, 2026 |
| Marina Escudero | Vice President, and Head of Clinical Operations · Since at least Nov 4, 2026 |
| Paul Little | Chief Financial Officer · Since at least Nov 4, 2026 |
| Sepideh Habibi | Vice President, and Head of Safety & Pharmacovigilance · Since at least Nov 4, 2026 |
| Steven Perrin | President, Director · Since at least Jul 31, 2026 |
| Steven Perrin | President and Chief Scientific Officer · Since at least Mar 4, 2026 |
| Yulan Li | Vice President, Biometrics · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Eledon Pharmaceuticals, Inc.